IFx-2.0, an innate immune agonist, targets resistance to immune checkpoint inhibitors in advanced cutaneous melanoma, receiving FDA orphan drug designation. Phase 1 trials showed IFx-2.0's safety and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results